Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

Gerhard Dickneite; Maureane Hoffman

doi:10.1160/TH13-05-0431

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 111(02): 189-198
DOI: 10.1160/TH13-05-0431

Review Article

Schattauer GmbH

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

Gerhard Dickneite

¹CSL Behring, Preclinical R&D, Marburg, Germany

,

Maureane Hoffman

²Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA

› Author Affiliations

Abstract

Summary

Newer oral anticoagulants offer several advantages over traditional agents (e.g. warfarin), but they are still associated with a bleeding risk and currently there is no validated reversal treatment for them. While there is little support for the use of fresh frozen plasma, and limited data available on the effects of activated recombinant factor VII, preclinical data suggest that prothrombin complex concentrates (PCCs) may have potential in this setting. PCCs are currently used to successfully reverse warfarin-induced anticoagulation; however, clinical evidence for their use with new oral anticoagulants is lacking, with most of the available data coming from preclinical animal studies. Furthermore, there appears to be variation in the ability of different PCCs to reverse the coagulopathy induced by the new anticoagulants, and a lack of correlation between the reversal of laboratory test results and the reversal of anticoagulant-induced bleeding. Although there have been encouraging results, care must be taken in generalising findings from animal models and nonbleeding human subjects to the situation in bleeding patients. Ultimately, more evidence supporting anticoagulation reversal for new anticoagulants is needed, particularly regarding the treatment of bleeding in human patients in a clinical setting. According to the current evidence, use of PCCs may be considered a reasonable approach in dire clinical situations; however, a consensus has not yet been reached regarding PCC use or dosing, due to lack of clinical data.

Keywords

Prothrombin complex concentrate - direct thrombin inhibitors - FXa inhibitors - new oral anticoagulants - anticoagulant reversal

Full Text

References

References
1 Nutescu EA, Shapiro NL, Chevalier A. et al. A pharmacologic overview of current and emerging anticoagulants. Cleve Clin J Med 2005; 72 (Suppl. 01) S2-S6.
2 Ahrens I, Peter K, Lip GY. et al. Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugs. Discov Med 2012; 13: 433-443.
3 Samama MM. The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. Thromb Res 2011; 127: 497-504.
4 Ahrens I, Peter K, Lip GY. et al. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. Discov Med 2012; 13: 445-450.
5 Moser M, Bode C. Anticoagulation in atrial fibrillation: a new era has begun. Hämostaseologie 2012; 32: 37-39.
6 Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Ann Rev Med 2011; 62: 41-57.
7 Battinelli EM. Reversal of new oral anticoagulants. Circulation 2011; 124: 1508-1510.
8 Makris M, van Veen JJ. Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal?. Blood Transfus 2011; 9: 117-119.
9 Boulis NM, Bobek MP, Schmaier A. et al. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45: 1113-1119.
10 Cartmill M, Dolan G, Byrne JL. et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14: 458-461.
11 Demeyere R, Gillardin S, Arnout J. et al. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010; 99: 251-260.
12 Fredriksson K, Norrving B, Stromblad L. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23: 972-977.
13 Makris M, Greaves M, Phillips WS. et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-480.
14 Yasaka M, Sakata T, Naritomi H. et al. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Throm Res 2005; 115: 455-459.
15 Board of the German Medical Association.. Cross-sectional guidelines for therapy with blood components and blood derivatives; plasma for therapeutic use. Transfus Med Hemother 2009; 26: 388-397.
16 Holbrook A, Schulman S, Witt DM. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152S-84S.
17 Keeling D, Baglin T, Tait C. et al. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol 2011; 154: 311-324.
18 Pernod G, Godier A, Gozalo C. et al. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010; 126: e167-174.
19 Spahn DR, Bouillon B, Cerny V. et al. Management of bleeding and coagulo-pathy following major trauma: an updated European guideline. Crit Care 2013; 17: R76
20 Kaatz S, Kouides PA, Garcia DA. et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 (Suppl. 01) S141-S145.
21 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
22 Marlu R, Hodaj E, Paris A. et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
23 Hoffman M, Volovyk Z, Monroe D. Partial Reversal of Dabigatran Effect by a Prothrombin Complex Concentrate in a Model of Thrombin Generation. Blood (ASH Annual Meeting Abstracts) 2012; 120: 3420.
24 Tanaka KA, Szlam F, Dickneite G. et al. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res 2008; 122: 117-123.
25 Herzog E, Kaspereit F, Krege W. et al. Pre-clinical safety aspects on the use of Beriplex P/N for reversal of dabigatran anticoagulation. Poster session presented at: 57^th Annual Meeting of the German Thrombosis and Haemostasis (GTH) Research Society 2013 2013 Feb 20-23; Munich, Germany.:
26 Lambourne MD, Eltringham-Smith LJ, Gataiance S. et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost 2012; 10: 1830-1840.
27 Pragst I, Zeitler SH, Doerr B. et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10: 1841-1848.
28 van Ryn J, Schurer J, Kink-Eiband M. et al. The successful reversal of dabi-gatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood (ASH Annual Meeting Abstracts) 2011; 118: 2316.
29 Zhou W, Schwarting S, Illanes S. et al. Hemostatic therapy in experimental in-tracerebral hemorrhage associated with the direct thrombin inhibitor dabi-gatran. Stroke 2011; 42: 3594-3599.
30 van Ryn J, Schurer J, Kink-Eiband M. et al. Successful reversal of dabigatran-in-duced bleeding by 3-factor coagulation concentrates in a rat tail bleeding model: lack of correlation with ex vivo markers of anticoagulation. Oral session presented at: American Heart Association (AHA) Scientific Sessions and Resuscitation Science Symposium; 2012 Nov 3–5; Los Angeles, CA, USA.:
31 Dinkelaar J, Molenaar PJ, Ninivaggi M. et al. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban. J Thromb Haemost 2013; 11: 1111-1118.
32 Zhou W, Zorn M, Nawroth P. et al. Hemostatic therapy in experimental intra-cerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44: 771-778.
33 Perzborn E, Gruber A, Tinel H. et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013; 110: 162-172.
34 Godier A, Miclot A, Le Bonniec B. et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102.
35 Fukuda T, Honda Y, Kamisato C. et al. Reversal of anticoagulant effects of edox-aban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Hae-most 2012; 107: 253-259.
36 Bauersachs R, Berkowitz SD, Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
37 Büller HR, Prins MH, Lensing AWA. et al. Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies. Blood (ASH Annual Meeting Abstracts) 2012; 120: 20.
38 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
39 Kawaji H, Ishii M, Tamaki Y. et al. Edoxaban for prevention of venous throm-boembolism after major orthopedic surgery. Orthop Res Rev 2012; 4: 53-64.
40 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvu-lar atrial fibrillation. N Engl J Med 2011; 365: 883-891.
41 Schulman S, Kearon C, Kakkar AK. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
42 Schulman S, Kearon C, Kakkar AK. et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-718.
43 Miesbach W, Seifried E. New direct oral anticoagulants – current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012; 108: 625-632.
44 Huisman MV, Lip GY, Diener HC. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
45 Levy JH, Faraoni D, Spring JL. et al. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013; 118: 1466-1474.
46 Heidbuchel H, Verhamme P, Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
47 Turpie AG, Kreutz R, Llau J. et al. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108: 876-886.
48 Pengo V, Crippa L, Falanga A. et al. Questions and answers on the use of dabi-gatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
49 Ahmad Y, Lip GYH. Anticoagulation in atrial fibrillation. Arrhythmia Electro-physiol Rev 2012; 1: 12-16.
50 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451.
51 van Ryn J, Litzenburger T, Waterman A. et al. An antibody selective to dabi-gatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models. J Thromb Haemost 2011; 9 (Suppl. 02) 1-970.
52 Perzborn E, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. J Thromb Haemost 2009; 7: 379.
53 Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract 2008; 62: 1614-1622.
54 Baglin T, Hillarp A, Tripodi A. et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013 Epub ahead of print.
55 Dentali F, Marchesi C, Pierfranceschi MG. et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106: 429-438.
56 Sorensen B, Spahn DR, Innerhofer P. et al. Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity. Crit Care 2011; 15: 201.
57 Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood 2011; 117: 6091-6099.
58 CSL Behring.. Prothrombinex^®-VF Product Information. Available at: http://www.csl.com.au/docs/515/128/10%2000%20(3),0.pdf. Accessed July, 2013.
59 Hori M, Matsumoto M, Tanahashi N. et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study. Circ J 2012; 76: 2104-2111.
60 Büller HR, Prins MH, Lensin AW. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
61 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
62 Lopes RD, Al-Khatib SM, Wallentin L. et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in at-rial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012; 380: 1749-1758.
63 Lassen MR, Raskob GE, Gallus A. et al. Apixaban or enoxaparin for thrombo-prophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
64 Lassen MR, Gallus A, Raskob GE. et al. Apixaban versus enoxaparin for throm-boprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-2498.
65 Herzog E, Kaspereit F, Krege W. et al. Pre-clinical safety aspects on the use of Beriplex P/N for reversal of Dabigatran anticoagulation. Poster session presented at: 57^th Annual Meeting of the German Thrombosis and Haemostasis (GTH) Research Society 2013 2013 Feb 20-23; Munich, Germany.: